Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aTRPA1
- Development stage
- Preclinical
- Lead developer
- Oblique Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
aTRPA1 is a preclinical-stage monoclonal antibody developed by Oblique Therapeutics for the treatment of pain. It targets the Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel, a member of the TRP family of ion channels that acts as a sensor for noxious stimuli and is involved in the development of inflammatory and neuropathic pain. The antibody was identified using Oblique's proprietary Abiprot platform, which is designed to discover functional antibodies against difficult-to-target membrane proteins like ion channels and GPCRs. By inhibiting TRPA1, aTRPA1 aims to provide a novel analgesic therapy with a high degree of specificity and potentially fewer side effects than traditional pain medications.
- Other names
- anti-TRPA1 antibodyanti-TRPA-1 antibodyanti-TRPA 1 antibody
02
Targets
TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on aTRPA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aTRPA1.